Japan is the next destination for global drug development

Wednesday, Nov. 18, 2026 | 11 a.m. - 1 p.m. ET

Regulatory reforms are underway. The PMDA has opened an office in Washington, DC. Funding programs are structured to double venture investment in eligible biotechs, and 2026 changes are reshaping the pricing system.

Endpoints News and Nikkei Biotechnology & Business have built this year's event around financing, commercialization, startup formation and the partnerships connecting Japanese science and global biopharma. Hear it directly from senior regulators, company leaders and investors. Join us.

SPONSORED BY